Zentalis Pharmaceuticals, Inc. (ZNTL) is an innovative biopharmaceutical company committed to designing and developing innovative treatments for cancer patients. The company, which has its principal operations in the United States and China, is engaged in the discovery, development, and commercialization of clinically differentiated, novel therapies targeted for patients suffering from various cancer types.
Established in 2014, the company brings together a world-class team of experts and a robust portfolio of clinical-stage drug candidates to relentlessly pursue a singular goal: to improve the lives of cancer-stricken people worldwide. As of today, Zentalis Pharmaceuticals has accelerated multiple programs into and through the clinic effectively, implementing an unparalleled operational execution that allowed Zentalis to rapidly move a strong pipeline of four clinical-stage oncology candidates forward.
The core objective of Zentalis Pharmaceuticals is to discover and develop transformative therapies addressing critical unmet patient needs. ZNTL’s most advanced product candidate, ZN-c5, is an oral SERD (Selective Estrogen Receptor Degrader) for estrogen receptor-positive, HER2-negative breast cancer, for which a Phase 1/2 clinical trial is ongoing. Additionally, ZNTL’s ZN-c3, an inhibitor of the WEE1 enzyme, is being tested in a Phase 1/2 clinical trial for the treatment of advanced solid tumors.
Zentalis Pharmaceuticals, Inc. went public in April 2020, listing its shares on the Nasdaq Global Market under the symbol "ZNTL". Since then, ZNTL has invested heavily in its research activities with the aim of producing innovative and promising solutions for the treatment of cancer.
Zentalis Pharmaceuticals, Inc. values meaningful collaborations. Its subsidiary, Zentera Therapeutics, is stationed in Shanghai, China, and operates on a parallel drug development strategy. These collaborations enable the innovation of cutting-edge treatments in both Western and Chinese markets simultaneously, which potentially expedient the development process, enabling more cancer patients to access their innovative medicine as quickly as possible.
Overall, Zentalis Pharmaceuticals, Inc. operates with a clear vision – to produce treatments that will change the lives of people living with cancer. The company utilizes advanced technology and works in collaboration with some of the industry’s leading professionals to ensure that life-saving treatments are developed and made available to patients across the globe.